Efficacy of Imatinib Mesylate Treatment for a Patient with Rheumatoid Arthritis and Who Developed Chronic Myelogenous Leukemia
Journal of Rheumatic Diseases
;
: 118-121, 2011.
Article
Dans Coréen
| WPRIM
| ID: wpr-189382
ABSTRACT
Rheumatoid arthritis is associated with an increased risk of hematological malignancy as a result of the RA itself or its treatment. We report here on an unusual case of a 55-year-old female with long-standing rheumatoid arthritis and who was treated with low dose methotrexate and hydrochloroquine. She was diagnosed with chronic myelogenous leukemia that manifested with severe thrombocytosis and basophilia, and this was treated with imatinib mesylate. After 6 months, she achieved a complete cytogenetic response of the CML and a complete resolution of all the RA symptoms without DMARDs.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Pipérazines
/
Polyarthrite rhumatoïde
/
Pyrimidines
/
Thrombocytose
/
Benzamides
/
Leucémie myéloïde chronique BCR-ABL positive
/
Méthotrexate
/
Méthanesulfonates
/
Antirhumatismaux
/
Tumeurs hématologiques
Limites du sujet:
Femelle
/
Humains
langue:
Coréen
Texte intégral:
Journal of Rheumatic Diseases
Année:
2011
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS